-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
FY2022 Earnings Forecast for Alaunos Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:TCRT)
FY2022 Earnings Forecast for Alaunos Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:TCRT)
Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) – Research analysts at Cantor Fitzgerald raised their FY2022 EPS estimates for Alaunos Therapeutics in a research note issued on Tuesday, January 10th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($0.17) for the year, up from their previous estimate of ($0.18). The consensus estimate for Alaunos Therapeutics' current full-year earnings is ($0.16) per share. Cantor Fitzgerald also issued estimates for Alaunos Therapeutics' FY2023 earnings at ($0.16) EPS.
Get Alaunos Therapeutics alerts:Separately, Wells Fargo & Company reiterated an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a report on Tuesday, October 4th.
Alaunos Therapeutics Price Performance
Alaunos Therapeutics stock opened at $0.80 on Friday. The firm has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $1.40. The stock has a market capitalization of $172.36 million, a PE ratio of -4.20 and a beta of 0.07. Alaunos Therapeutics has a 12-month low of $0.41 and a 12-month high of $4.01.Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $2.91 million during the quarter.
Insider Buying and Selling
In other Alaunos Therapeutics news, Director Robert W. Postma bought 750,000 shares of Alaunos Therapeutics stock in a transaction that occurred on Tuesday, November 29th. The stock was purchased at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the completion of the acquisition, the director now owns 5,000,000 shares of the company's stock, valued at approximately $3,250,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.90% of the stock is currently owned by insiders.
Institutional Trading of Alaunos Therapeutics
A number of large investors have recently added to or reduced their stakes in the business. Discovery Capital Management LLC CT bought a new stake in Alaunos Therapeutics during the second quarter worth approximately $17,515,000. Laurion Capital Management LP acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $5,319,000. JPMorgan Chase & Co. acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $5,231,000. State Street Corp boosted its stake in Alaunos Therapeutics by 268.3% in the 3rd quarter. State Street Corp now owns 3,178,423 shares of the company's stock worth $5,467,000 after purchasing an additional 2,315,397 shares during the period. Finally, Millennium Management LLC acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $2,690,000. 34.36% of the stock is currently owned by institutional investors.
Alaunos Therapeutics Company Profile
(Get Rating)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
See Also
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) – Research analysts at Cantor Fitzgerald raised their FY2022 EPS estimates for Alaunos Therapeutics in a research note issued on Tuesday, January 10th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($0.17) for the year, up from their previous estimate of ($0.18). The consensus estimate for Alaunos Therapeutics' current full-year earnings is ($0.16) per share. Cantor Fitzgerald also issued estimates for Alaunos Therapeutics' FY2023 earnings at ($0.16) EPS.
阿拉諾斯治療有限公司(NASDAQ:TCRT — 獲得評分)— 坎特菲茨杰拉德的研究分析師在 1 月 10 日(星期二)發布的研究報告中提出了阿拉諾斯治療的 FY2022 EPS 估計。坎特·菲茨杰拉德分析師阿格拉爾德現在預計,該公司將張貼每股收益($0.17)的年度,從他們以前的估計(0.18 美元)上升。阿拉努斯治療當前全年收益的共識估計為每股(0.16 美元)。坎特·菲茨杰拉德還發布了阿勞諾斯治療的 FY2023 收益的估計值,每股收益為 0.16 美元。
Separately, Wells Fargo & Company reiterated an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a report on Tuesday, October 4th.
另外,富國銀行公司在 10 月 4 日(星期二)的一份報告中重申了「超重」評級,並對 Alaunos 治療藥物的股票發布了 3.00 美元的價格目標。
Alaunos Therapeutics Price Performance
阿拉努斯治療價格表現
Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $2.91 million during the quarter.
阿勞諾斯治療(NASDAQ:TCRT-獲取評級)上次公佈其季度收益業績於 11 月 14 日(星期一)。該公司報告了本季度每股收益(0.04 美元),超過了 0.08 美元的共識估計(0.12 美元)。該公司在本季度的收入為 2.91 萬美元。
Insider Buying and Selling
內幕買賣
In other Alaunos Therapeutics news, Director Robert W. Postma bought 750,000 shares of Alaunos Therapeutics stock in a transaction that occurred on Tuesday, November 29th. The stock was purchased at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the completion of the acquisition, the director now owns 5,000,000 shares of the company's stock, valued at approximately $3,250,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.90% of the stock is currently owned by insiders.
在其他阿勞諾斯治療新聞中,導演羅伯特 ·W· 波斯特馬在 11 月 29 日(週二)進行的一項交易中購買了 75 萬股阿勞諾斯治療股票。該股票以每股 0.65 美元的平均成本購買,總交易額為 487,500.00 美元。收購完成後,董事現在擁有該公司 5,000,000 股股份,價值約 3,250,000 美元。該收購已在向證券交易委員會提交的文件中披露,該文件可通過以下方式獲得 這個鏈接。4.90% 的股票目前由內部人士擁有。
Institutional Trading of Alaunos Therapeutics
阿拉烏諾斯治療的機構交易
A number of large investors have recently added to or reduced their stakes in the business. Discovery Capital Management LLC CT bought a new stake in Alaunos Therapeutics during the second quarter worth approximately $17,515,000. Laurion Capital Management LP acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $5,319,000. JPMorgan Chase & Co. acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $5,231,000. State Street Corp boosted its stake in Alaunos Therapeutics by 268.3% in the 3rd quarter. State Street Corp now owns 3,178,423 shares of the company's stock worth $5,467,000 after purchasing an additional 2,315,397 shares during the period. Finally, Millennium Management LLC acquired a new position in Alaunos Therapeutics in the 2nd quarter worth approximately $2,690,000. 34.36% of the stock is currently owned by institutional investors.
一些大型投資者最近增加或減少了他們在業務中的賭注。發現資本管理有限責任公司 CT 在第二季度購買了阿拉烏諾斯治療的新股份,價值約為 17,515,000 美元。勞永資本管理有限責任公司在第二季度收購了阿勞諾斯治療的新位置,價值約為 $5,319,000.摩根大通公司於第二季度收購了阿拉諾斯治療的新職位,價值約為 5,231,000 美元。州街公司在第三季度將其在阿拉烏諾斯治療的股份提高了 268.3%。在期內另外購買 2,315,397 股股份後,州街公司現在擁有該公司股票價值 5,467,000 元的 3,178,423 股股份。最後,千禧年管理有限責任公司在第二季度收購了 Alaunos 治療的新職位,價值約為 2,690,000 美元。目前,該股票的 34.36% 由機構投資者擁有。
Alaunos Therapeutics Company Profile
阿拉烏諾斯治療公司簡介
(Get Rating)
(取得評分)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
Alaunos 治療, Inc 是一家以臨床階段腫瘤學為中心的細胞治療公司,開發採用 TCR 工程 T 細胞療法。該公司開發了 TCR 圖書館,該圖書館在其 TCR 庫中針對非小細胞肺,結直腸癌,子宮內膜,胰腺癌,卵巢癌和膽管癌反應十 TCR 進行 I/II 期臨床試驗;HunTR 是一種人類腫瘤抗原 T 細胞受體受體平台;以及 mBIL15 治療腫瘤。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
- 獲取有關阿拉胡諾斯治療(TCRT)的研究報告的免費副本
- 市場節拍:評論中的一周
- 摩根大通下跌,銀行為經濟衰退做好準備
- 為什麼床浴及超越股票價格上漲 261%?
- Roku 股票價格趨勢,這就是為什麼
- 卡瓦納股票拉力賽,這是您需要知道的
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收阿拉努斯治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Alaunos 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧